WE SEE THE FUTURE FIRST

WE SEE THE FUTURE FIRST

Minerva Biotechnologies is focused on cancer and stem cell therapeutics. We are developing cancer immunotherapies targeting 80% of solid tumors and to prevent cancer metastasis

more info
patternframe

Welcome to Minerva Biotechnologies

Exploring the Space between Cancers and Stem Cells

Cancer Therapeutics

Cancer Therapeutics

Minerva's CAR T therapeutics will attack solid tumors that are MUC1* positive. This represents approximately 80% of all cancers.

learn more
Regenerative Medicine

Regenerative Medicine

Minerva’s stem cell discoveries will enable pharmaceutical companies to utilize regenerative medicine in a variety of diseases

learn more
Stem Cells

Stem Cells

Using NME7AB, iPSC generation is 50x more efficient, cell growth is more scalable, and resulting cells have improved functionality

learn more

We See The Future First.

Minerva Attending the J.P. Morgan 35th Annual Healthcare Conference 2017 in San Francisco

featured news

Minerva Attending the J.P. Morgan 35th Annual Healthcare Conference 2017 in San Francisco

The Minerva team will be taking meetings at the J.P. Morgan Healthcare Conference in San Francisco January 9th - 13th, 2017. This event continues...

Posted on January 4, 2017

view more DETAILS

Latest News

January 4, 2017

Minerva Attending the J.P. Morgan 35th Annual Healthcare Conference 2017 in San Francisco

The Minerva team will be taking meetings at the J.P. Morgan Healthcare Conference in San

November 7, 2016

Job Opening - Research Scientist, Immunotherapy​

Research Scientist,  Immunotherapy​ It started with a simple hypothesis

September 26, 2016

Minerva Presenting at 10yrs of iPSCs Symposium 

Dr. Cynthia Bamdad, CEO and Founder of Minerva Biotechnologies, will be presenting a

View All News

We See The Future First.

Sign Up For Our Mailing List.